Combined Positron Emission Tomography/Computed Tomography in Sunitinib Therapy Assessment of Patients with Metastatic Renal Cell Carcinoma

In patients with mRCC, a high baseline 18F-FDG uptake indicates aggressive disease, and the degree of reduction in 18F-FDG uptake after sunitinib treatment adds valuable prognostic information. Hence, the inclusion of PET results seems to improve the clinical counselling of patients with mRCC. Larger studies are needed to confirm these findings.